The U.S. Food and Drug Administration has granted accelerated approval to a new targeted therapy for patients with advanced HER2-positive breast cancer. The decision follows encouraging results from a pivotal phase 3 clinical trial, marking another option for people facing a difficult-to-treat form of the disease.

HER2-positive breast cancer is driven by excessive levels of the HER2 protein, which can fuel rapid tumor growth. Targeted therapies have changed treatment for many patients, but advanced cases can remain challenging, especially when the cancer stops responding to earlier drugs.

Accelerated approval allows the medicine to reach patients sooner when early evidence suggests meaningful benefit in serious or life-threatening conditions. Regulators will still require additional data to confirm the treatment's clinical advantage over time.

For patients and oncologists, the approval adds a new weapon in the fight against advanced breast cancer and underscores the continuing push for therapies that can extend survival and improve quality of life.